ESMO 2024: 9 professionals from the Centre Baclesse showcase their advances

Several professionals from the Centre Baclesse took part inESMO 2024 (European Society for Medical Oncology), held in Barcelona from September 13 to 17. This not-to-be-missed event brings together the major international players in the field of oncology for exchanges and conferences. Oral and poster presentations by professionals from the Centre Baclesse enriched the congress with their innovative approach, scientific rigor and commitment to continuous improvement in patient care.

Sessions include oral presentations, scientific posters, workshops and symposia, encouraging the exchange of ideas and the development of international collaborations. In addition, the congress enables participants to keep abreast of new guidelines and recommendations, contributing to the continuous improvement of patient care.

Oral presentations

• Dr. François Cherifi, head of medical oncology at the Baclesse Center, gave a mini-oral presentation on his study: "PROMENADE: Pembrolizumab for early ER-low/HER2- breast cancer, real-world French cohort."

• Pr Florence JOLY, Scientific Director of the Centre Baclesse, in an oral presentation during a special session:
  "How can technology help the fight? Digitizing the patient journey in gynaecology".

• Participation of the digestive UCP at the Baclesse Center (Dr. Stéphane CORBINAIS, medical oncologist and head of the 7th floor hospitalization unit; as co-author) in the POCHI trial presented in an oral communication:
  POCHI trial: "2785; Pembrolizumab in combination with CAPOX and bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: preliminary results of FFCD 1703 POCHI trial"

The posters

• Louis BOISMOREAU, medical oncology intern at the Baclesse Center, presented a meta-analysis on the cardiovascular effects of CDK4/6 inhibitors, particularly in breast cancer:
  "Cardiovascular Adverse events related to CDK4/6 Inhibitors: a systematic review and safety meta-analysis of randomized controlled trials"
  Louis BOISMOREAU, Charles DOLLADILLE, Etienne BASTIEN, Pierre-Marie MORICE, George EMILE, Thomas RUHSTALLER, Joachim ALEXANDRE, Angélique DA SILVA

• Dr. Elodie COQUAN, medical oncologist at the Baclesse Center
  "Efficacy of talazoparib and avelumab as a maintenance treatment in patients with advanced/metastatic urothelial carcinoma (mUC) whose disease did not progress after a first-line platinum-based chemotherapy (PBCT): The GETUG-TALASUR trial"

• Prof. Florence JOLY, Scientific Director of the Baclesse Center
  "Epidemiology and treatment patterns of patients with locally advanced or metastatic urothelial cancer in France: a non-interventional database study"

•  Antoine BOUE, neuropsychologist , and Professor Florence JOLY, Scientific Director at the Baclesse Center
  "Impact of androgen pathway inhibitors on cognitive function in elderly patients with metastatic prostate cancer: results from the COG-PRO trial"

• Valentin HARTER, Biostatistician for the Cancer Research Center Data Processing Center of Northwest France, and Dr. Dominique VAUR, former director of the Cancer Biology and Genetics Laboratory at the Baclesse Center ( ARCAGY-GINECO study)
  "Reclassification and variant distribution in the GINECO GREAT study of ovarian cancer patients: insights into HRD status "
  Etienne ROULEAU, Isabelle SOUBEYRAN, Véronique HADDAD, Valentin HARTER, Adrien BUISSON, Romain BOIDOT, Louise-Marie CHEVALIER, Alexandra LESPAGNOL, Celine CALLENS, Sophie MANZ, Pierre-Jean LAMY, Karen LEROY, Anne TALLET, Othman LAGHMARI, Jacqueline LEHMANN-CHE, Christine TOULAS, Alexandre HARLE, Eric PUJADE-LAURAINE, Thibault DE LA MOTTE ROUGE, Dominique VAUR

• Prof. Juliette THARIAT, radiation oncologist at the Baclesse Center
  "Cost effectiveness of stereotactic ablative radiotherapy (SABR) alone in comparison with systemic treatment and SABR in oligometastatic head and neck cancer in the GORTEC 2014-04 OMET randomized phase II study."

Congratulations to all of you for your valuable contributions!